Phase 2 study of bortezomib±docetaxel in advanced non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Fanucchi, M
Fossella, F
Fidias, P
Natale, R
Belt, R
Govindan, R
Raez, L
Schiller, J
Kashala, O
Kelly, K
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Cedars Sinai Comprehens Canc Ctr, Los Angeles, CA USA
[5] Kansas City Oncol Hematol Grp, Kansas City, MO USA
[6] Washington Univ, St Louis, MO USA
[7] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33152 USA
[8] Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA
[9] Millennium Pharmaceut Inc, Cambridge, MA USA
[10] Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)80217-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S30 / S30
页数：1
相关论文
共 50 条
  • [1] Bortezomib ± docetaxel in previously treated advanced non-small cell lung cancer: Interim analysis of a phase 2 study
    Fanucchi, Michael
    Belt, Robert
    Fossella, Frank
    Natale, Ronald
    Robert, Francisco
    Fidias, Panos
    Kelly, Karen
    Kashala, Oscar
    Schenkein, David
    Schiller, Joan
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 170 - 170
  • [2] Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC):: Preliminary results.
    Fanucchi, MP
    Belt, RJ
    Fossella, FV
    Natale, RB
    Robert, F
    Fidias, P
    Kelly, K
    Kashala, O
    Shenkein, DP
    Schiller, JH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 643S - 643S
  • [3] Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer
    Besse, Benjamin
    Planchard, David
    Veillard, Anne-Sophie
    Taillade, Laurent
    Khayat, David
    Ducourtieux, Muriel
    Pignon, Jean-Pierre
    Lumbroso, Jean
    Lafontaine, Carole
    Mathiot, Claire
    Soria, Jean-Charles
    [J]. LUNG CANCER, 2012, 76 (01) : 78 - 83
  • [4] A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)
    Sovak, M. A.
    Lutzker, S.
    Guensch, L.
    Joyce, M.
    Schwartz, S.
    Wu, Y.
    Zheng, L.
    Aisner, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] A phase II study of nedaplatin (CDGP) and docetaxel (TXT) in patients with advanced non-small cell lung cancer (NSCLC)
    Fujino, S.
    Asada, Y.
    Nakano, Y.
    Suzumura, Y.
    Inoue, S.
    Nagao, T.
    Hajiro, T.
    Tezuka, N.
    Sawai, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Phase II study of Docetaxel (D) and Carboplatin (C) combination in advanced Non-Small Cell Lung Cancer (NSCLC)
    Chowdhury, Qamruzzaman
    Begum, Ferdous A.
    Nahar, Ferdous
    Fairuz, Saima
    Faruqui, Mesba
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S673 - S673
  • [7] Docetaxel in advanced non-small cell lung cancer
    Wakelee, H
    Ramalingam, S
    Belani, CP
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (01) : 13 - 24
  • [8] Preliminary report of a phase II study of docetaxel (taxotere(R) and cisplatin in advanced non-small cell lung cancer (NSCLC)
    Douillard, JY
    Monnier, A
    Ibrahim, N
    Belli, L
    Sun, XS
    Soulas, F
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1096 - 1096
  • [9] Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC)
    Belani, C. P.
    Ramalingam, S.
    Schreeder, M.
    Steis, R.
    Guidice, R.
    Marshland, T.
    Butler, B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Phase I study of apatinib combined with docetaxel in EGFR-negative advanced non-small cell lung cancer (NSCLC)
    Duan, Jianchun
    Wang, Jie
    Wang, Zhijie
    Lin, Lin
    Li, Junling
    Wang, Yan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345